Nu-Med Plus to merge with YourSpace America; YSA's Colvin to become CEO with majority voting control

Nu-Med Plus, Inc.

4,500,000 Series A Preferred shares (20:1 voting, convertible into 20 common each) issued to YSA shareholders at closing.
1,000,000 Series X Preferred shares (100:1 voting, non-convertible) issued to YSA CEO Russ Colvin, granting majority voting control.
Upon closing, Colvin becomes President, CEO, Director; William Hayde named Executive Chairman; Merrell and Robins continue as Directors.
Closing subject to final due diligence; no purchase price or financial terms disclosed.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Nu-Med Plus, Inc. entered into Share Exchange Agreement with YourSpace America, Inc. (effective 2024-04-25).

Action: entry
Agreement: merger
Counterparty: YourSpace America, Inc.
Effective: 2024-04-25

Exact text from the filing

On April 25, 2024, Nu-Med Plus, Inc. (the " Company ") entered into a Share Exchange Agreement (the " Share Exchange Agreement ") for the merger of YourSpace America, Inc. (" YSA ") into the Company (the " Transaction ").

View on SEC.gov

246 material agreements filed in the last 30 days. Browse all material agreements →

Nu-Med Plus, Inc. filing history →

Source: SEC EDGAR

accession 0001548123-24-000062

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.